Leqembi

Lecanemab, the active ingredient in Leqembi, is a humanized monoclonal antibody presented as an intravenous solution for infusion for intravenous use. It is indicated for the treatment of Alzheimer’s disease in patients with early symptomatic disease who have confirmed amyloid pathology. GNH USA supplies Leqembi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leqembi is a disease‑modifying therapy that targets amyloid pathology in Alzheimer’s disease.

Alzheimer’s disease (early symptomatic): reduces amyloid plaque burden and may slow cognitive decline. Mild cognitive impairment due to Alzheimer’s pathology: may delay progression to overt dementia. Early‑stage Alzheimer’s disease: intended for patients with confirmed amyloid accumulation.

Leqembi may be associated with a range of adverse reactions observed during clinical use.

Common Side Effects: - Infusion‑related reactions (e.g., flushing, chills, nausea). - Headache. - Mild dizziness. - Transient fever. - Fatigue. - Mild rash.

Serious or Rare Side Effects: - Amyloid‑related imaging abnormalities (ARIA‑E or ARIA‑H). - Severe hypersensitivity or anaphylaxis. - Intracerebral hemorrhage. - Severe thrombocytopenia. - Acute kidney injury. - Severe edema or pulmonary edema.

Prior to initiating therapy, clinicians should evaluate patient suitability and monitor for known risks. - Patient selection: confirm amyloid pathology with PET or CSF biomarkers before starting. - MRI monitoring: perform baseline and periodic MRIs to detect ARIA. - Anticoagulant use: assess bleeding risk and consider alternative strategies. - Renal function: evaluate kidney function as impaired clearance may affect safety. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lecanemab may interact with other agents that influence bleeding risk or immune response.

Major Interactions (Avoid): - Concurrent anticoagulants or antiplatelet agents: increased risk of intracerebral hemorrhage. - Other amyloid‑targeting antibodies: additive risk of ARIA. - Live vaccines: may reduce vaccine efficacy.

Moderate Interactions (Monitor Closely): - Immunosuppressants: possible alteration of immune response. - CYP450 substrates: minimal effect but monitor for unexpected changes. - Non‑live vaccines: timing may need adjustment. - Herbal supplements affecting coagulation (e.g., ginkgo, garlic): monitor bleeding parameters.